Main focus: Allogeneic CAR-T cell therapies
Company stage: Clinical
Diseases: Non-hodgkins lymphoma (NHL), multiple myeloma (MM), acute myeloid leukemia (AML), renal cell carcinoma (RCC), small cell lung cancer (SCLC)
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:ALLO)
Location: San Francisco, CA, USA
Partners: Cellectis, SpringWorks Therapeutics, Pfizer
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing.
At Allogene, we are developing a pipeline of off-the-shelf CAR T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.